Table 3. Clinical features of classical Hodgkin lymphoma (CHL), polymorphic lymphoproliferative disorders (P-LPD), and non-specific LPD (NS-LPD).
| Subtype | Author | Year | N | Sex | Age | Basal disease | MTX duration | Clinical State | EBV | Comment | Ref | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Types | Duration | Ratio | Latency | ||||||||||||||||||||||||||||
| M | F | Mean | Range | RA | Other | Mean | Range | Mean | Range | I | II | III | IV | + | - | I | II | III | |||||||||||||
| MTX- CHL |
Kojima | 2006 | 3 | 1 | 2 | 37 | 52-63 | 3 | 14.7 | 9-28 | 8.3 | 7-9 | 1 | 0 | 2 | 0 | 2 | 1 | NR | 36 | |||||||||||
| Rizzi | 2009 | 7 | 1 | 6 | 45 | 6-70 | 5 | JRA 2 | 10 | 1-24 | 2.9 | 0.7-10 | 1 | 2 | 2 | 2 | 5 | 1 | NR | 40 | |||||||||||
| Loo | 2013 | 6 | 1 | 5 | 53 | 25-77 | 5 | PM 1 | NR | NR | 1 | 1 | 1 | 3 | 4 | 2 | NR | 72 | |||||||||||||
| Yamakawa | 2014 | 3 | 1 | 2 | 69 | 65-76 | 3 | NR | 3.9 | 2.3-5.5 | 0 | 2 | 1 | 0 | 1 | 2 | 0 | 2 | 0 | 42 | |||||||||||
| Kameda | 2014 | 2 | 1 | 1 | 72 | 65-79 | 2 | 10 | 8-12 | 11.5 | 15-18 | 0 | 0 | 0 | 2 | 1 | 1 | NR | 43 | ||||||||||||
| Takasumi | 2015 | 1 | 0 | 1 | 68 | - | 1 | - | 14 | - | 7 | - | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 73 | |||||||||
| Tsukazaki | 2017 | 1 | 0 | 1 | 88 | - | 1 | - | 14 | - | 6 | - | 0 | 0 | 0 | 1 | 1 | 0 | NR | 74 | |||||||||||
| Gion | 2017 | 17 | 4 | 13 | 65 | 84 | 17 | - | NR | NR | 4 | 0 | 8 | 5 | 14 | 3 | NR | 25 | |||||||||||||
| Eso | 2018 | 1 | 1 | 0 | 83 | - | 1 | - | 6 | - | 6 | - | 0 | 0 | 0 | 1 | 1 | 0 | NR | 75 | |||||||||||
| Tokuhira | 2018 | 10 | 3 | 7 | 65 | 53-79 | 10 | - | 15.5 | 5.6-39 | 5.8 | 2.8-5.6 | 0 | 1 | 1 | 8 | 8 | 2 | NR | 16 | |||||||||||
| Total | 51 | 13 | 38 | 62 | 48 | 3 | 13 | 5.6 | 7 | 6 | 15 | 23 | 38 | 12 | 0 | 3 | 0 | ||||||||||||||
| MTX-polymorphic LPD | Kojima | 2006 | 3 | 1 | 2 | 63 | 57-73 | 3 | - | NR | 3.3 | 2-5 | 3 | 0 | 0 | 0 | 3 | 0 | NR | P-LPD | 36 | ||||||||||
| Komatsuda | 2008 | 1 | 0 | 1 | 63 | - | 1 | - | 14 | - | 14 | - | 0 | 0 | 0 | 1 | 1 | 0 | NR | HLL | 81 | ||||||||||
| Rizzi | 2009 | 2 | 1 | 1 | 40 | 33-47 | 2 | - | 8 | 2.9-13 | 5 | 4.9-5 | 0 | 0 | 0 | 1 | 2 | 0 | NR | HLL | 40 | ||||||||||
| Tokuhira | 2012 | 1 | 1 | 0 | 69 | - | 1 | - | - | 1.1 | - | 0 | 0 | 1 | 0 | 1 | 0 | HLL | 19 | ||||||||||||
| Yamakawa | 2014 | 2 | 1 | 1 | 75 | 71-79 | 2 | - | NR | 8 | 8-8 | 1 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 1 | P-LPD | 42 | |||||||||
| Kawano | 2014 | 1 | 0 | 1 | 56 | - | 1 | - | 5 | - | 2.5 | - | 0 | 0 | 0 | 1 | ND | HLL | 44 | ||||||||||||
| Ohkura | 2015 | 1 | 1 | 0 | 70 | - | 1 | - | 20 | - | 8 | - | 1 | 0 | 0 | 0 | 1 | 0 | NR | HLL | 82 | ||||||||||
| Yamakawa | 2016 | 1 | 1 | 0 | 78 | - | 1 | - | 12 | - | 4 | - | 0 | 0 | 0 | 1 | 1 | 0 | NR | P-LPD | 83 | ||||||||||
| Tsukui | 2018 | 5 | 0 | 5 | 72 | 63-78 | 5 | - | NR | 10 | 2-15 | ND | 3 | 4 | 0 | NR | P-LPD | 84 | |||||||||||||
| Total | 17 | 6 | 11 | 65 | 17 | 0 | 11 | 7.2 | 5 | 0 | 2 | 7 | 15 | 0 | 1 | 0 | 1 | ||||||||||||||
| MTX- NS- LPD |
Tokuhira | 2018 | 9 | 4 | 5 | 65 | 45-80 | 8 | PV 1 | 16 | 5.4-37.8 | 8.9 | 4.2-16.3 | 3 | 3 | 0 | 3 | 4 | 3 | NR | 16 | ||||||||||
EBV, Epstein-Barr virus; NR, not recorded; RA, rheumatoid arthritis; JRA, juvenile rheumatoid arthritis; PM, polymyositis; PV, psoriasis vulgaris: Ref, reference.